Furthermore, integrating PBMC immunophenotyping with established biomarkers—such as PD-L1 expression or tumor mutational burden (TMB)—may offer a novel and potentially complementary strategy for selecting patients most likely to benefit from immunotherapy [2,10,11]. Here, CD274 is linked to neoplasm.